We encourage participation in research that aims to make a real difference in the lives of people living with cardiomyopathy.
This could mean participating in a clinical trial, reviewing patient information leaflets, completing a questionnaire, or even taking part in a focus group. By involving people with cardiomyopathy in research, we can ensure the patient perspective is addressed and ensure project outcomes are patient-focused.
We are here to support you to take part in a wide range of high-quality research studies from universities, NHS Trusts, and other accredited research institutions. Take a look at the list of opportunities below and contact the researchers directly for more information about how to get involved. There are usually set criteria for taking part and some people may not always meet the criteria of the study.
More opportunities to take part in research can also be found through the NIHR Be Part of Research page. If you are keen to take part in a clinical trial for a new therapy, we suggest you discuss this with your Healthcare Professional before signing up. Further information on patient participation in research is available from NHS Choices.
If you're a researcher looking for support with recruiting people with cardiomyopathy into your study, please email email@example.com.
University of Liverpool
Researchers at the University of Liverpool are looking for Public Advisors to support a newly funded NIHR project called Renal-HF. This project aims to improve kidney health in people living with heart failure by developing technology to predict how often each person with heart failure needs a kidney blood test. The researchers will work with healthcare professionals and patients to produce expert and consistent advice for GPs and nurses on how to adjust medicine dose and/or medicine type to keep both the heart and kidneys working together at their best.
If you are interested in joining the team or want to know more - please send a paragraph expressing your interest or requesting more information to: Alison Gummery at firstname.lastname@example.org. The closing Date for expression of interest is 6th May 2022.
Imperial College London and the Royal Brompton Hospital
Researchers at Imperial College London and the Royal Brompton Hospital are recruiting patients into a research study with a diagnosis of dilated cardiomyopathy, whose heart function remains impaired despite usual therapy. They want to see if a new antioxidant therapy called MitQ may help promote recovery in heart function by improving the function of mitochondria, the energy producing centres in patients’ hearts. For more information on this study and how to take part click here
Imperial College London
Heart Hive is a new database for individuals who have shown an interest in participating in clinical trials and attempts to match people with researchers looking for trial participants. If you would like to sign up, visit the Heart Hive website.
Queen Elizabeth Hospital Glasgow and the Royal Brompton Hospital London
This research study looks at the role of the Lamin gene in Dilated Cardiomyopathy. You can find out more about this project here. Clinical trials are being conducted at St Barts in London and the Queen Elizabeth Hospital in Glasgow and the Royal Brompton Hospital in London. If you are receiving treatment from these centres please ask your doctor about the trial.
University College London, KU Leuven, Maastrict University
Vascular dementia and heart failure represent major health burden to morbidity, mortality and quality of life.
Comorbidities (hypertension, aging, diabetes, etc.) affect all organs, but the brain and heart are especially sensitive to these chronic stresses resulting in cognitive impairment (a mental disorder) and heart failure (a non-mental disorder). These comorbidities also induce a reduction in microvascular density, called microvascular rarefaction. Diagnosis of microvascular rarefaction is limited by the inability to assess microvascular density. The CRUCIAL research project brings together a consortium of researchers, scientists and patients to develop a coordinated program to establish clinical tools to measure rarefaction and investigate the role of microvascular rarefaction in cognitive impairment and heart failure. You can find our more about this project here
Are you a parent of a child with paediatric cardiomyopathy? If so, you know first-hand that PCM is a rare and often devastating heart condition. MyClimb is a Natural History Study designed to collect and evaluate information on the course of cardiomyopathy in children and adolescents with the MYBPC3 genetic mutation. This study is sponsored by Tenaya Therapeutics, a biotechnology company committed to discovering, developing, and delivering curative therapies that address the underlying causes of heart disease. If you would like to find out more about this study please click here.